Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 317

1.

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.

Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, Hobbs HH.

J Biol Chem. 2007 Jun 22;282(25):18602-12. Epub 2007 Apr 23.

2.

Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding.

Gu HM, Adijiang A, Mah M, Zhang DW.

J Lipid Res. 2013 Dec;54(12):3345-57. doi: 10.1194/jlr.M041129. Epub 2013 Oct 8.

3.

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor.

Zhang DW, Garuti R, Tang WJ, Cohen JC, Hobbs HH.

Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13045-50. doi: 10.1073/pnas.0806312105. Epub 2008 Aug 27.

4.

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.

Urban D, Pöss J, Böhm M, Laufs U.

J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21. Review.

5.

PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.

Shan L, Pang L, Zhang R, Murgolo NJ, Lan H, Hedrick JA.

Biochem Biophys Res Commun. 2008 Oct 10;375(1):69-73. doi: 10.1016/j.bbrc.2008.07.106. Epub 2008 Jul 31.

PMID:
18675252
6.

Molecular basis for LDL receptor recognition by PCSK9.

Kwon HJ, Lagace TA, McNutt MC, Horton JD, Deisenhofer J.

Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1820-5. doi: 10.1073/pnas.0712064105. Epub 2008 Feb 4.

7.

Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification.

Tveten K, Holla ØL, Cameron J, Strøm TB, Berge KE, Laerdahl JK, Leren TP.

Hum Mol Genet. 2012 Mar 15;21(6):1402-9. doi: 10.1093/hmg/ddr578. Epub 2011 Dec 8.

PMID:
22156580
8.

Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.

Kosenko T, Golder M, Leblond G, Weng W, Lagace TA.

J Biol Chem. 2013 Mar 22;288(12):8279-88. doi: 10.1074/jbc.M112.421370. Epub 2013 Feb 11.

9.

The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.

Nassoury N, Blasiole DA, Tebon Oler A, Benjannet S, Hamelin J, Poupon V, McPherson PS, Attie AD, Prat A, Seidah NG.

Traffic. 2007 Jun;8(6):718-32. Epub 2007 Apr 25. Erratum in: Traffic. 2007 Jul;8(7):950.

10.

Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.

DeVay RM, Yamamoto L, Shelton DL, Liang H.

PLoS One. 2015 Apr 23;10(4):e0125127. doi: 10.1371/journal.pone.0125127. eCollection 2015.

11.

Sorting an LDL receptor with bound PCSK9 to intracellular degradation.

Leren TP.

Atherosclerosis. 2014 Nov;237(1):76-81. doi: 10.1016/j.atherosclerosis.2014.08.038. Epub 2014 Sep 2. Review.

PMID:
25222343
12.

New hypotheses about the structure-function of proprotein convertase subtilisin/kexin type 9: analysis of the epidermal growth factor-like repeat A docking site using WaterMap.

Pearlstein RA, Hu QY, Zhou J, Yowe D, Levell J, Dale B, Kaushik VK, Daniels D, Hanrahan S, Sherman W, Abel R.

Proteins. 2010 Sep;78(12):2571-86. doi: 10.1002/prot.22767.

PMID:
20589640
13.

Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels.

Mayer G, Poirier S, Seidah NG.

J Biol Chem. 2008 Nov 14;283(46):31791-801. doi: 10.1074/jbc.M805971200. Epub 2008 Sep 17.

14.

Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.

Fisher TS, Lo Surdo P, Pandit S, Mattu M, Santoro JC, Wisniewski D, Cummings RT, Calzetta A, Cubbon RM, Fischer PA, Tarachandani A, De Francesco R, Wright SD, Sparrow CP, Carfi A, Sitlani A.

J Biol Chem. 2007 Jul 13;282(28):20502-12. Epub 2007 May 10.

15.

Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route.

Poirier S, Mayer G, Poupon V, McPherson PS, Desjardins R, Ly K, Asselin MC, Day R, Duclos FJ, Witmer M, Parker R, Prat A, Seidah NG.

J Biol Chem. 2009 Oct 16;284(42):28856-64. doi: 10.1074/jbc.M109.037085. Epub 2009 Jul 27.

16.

A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9.

Holla ØL, Strøm TB, Cameron J, Berge KE, Leren TP.

Mol Genet Metab. 2010 Feb;99(2):149-56. doi: 10.1016/j.ymgme.2009.09.012. Epub 2009 Sep 27.

PMID:
19828345
17.

β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.

Starr AE, Lemieux V, Noad J, Moore JI, Dewpura T, Raymond A, Chrétien M, Figeys D, Mayne J.

FEBS J. 2015 Jul;282(14):2682-96. doi: 10.1111/febs.13309. Epub 2015 May 18.

18.

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.

Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A.

Hepatology. 2008 Aug;48(2):646-54. doi: 10.1002/hep.22354.

PMID:
18666258
19.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).

Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG.

PLoS One. 2013 May 13;8(5):e64145. doi: 10.1371/journal.pone.0064145. Print 2013.

20.

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH.

Lo Surdo P, Bottomley MJ, Calzetta A, Settembre EC, Cirillo A, Pandit S, Ni YG, Hubbard B, Sitlani A, Carfí A.

EMBO Rep. 2011 Dec 1;12(12):1300-5. doi: 10.1038/embor.2011.205.

Supplemental Content

Support Center